CoChat

Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils

Open access
Abskharon, Romany, Pan, Hope, Sawaya, Michael R., Seidler, Paul M., Olivares, Eileen J., Chen, Yu, Murray, Kevin A., Zhang, Jeffrey, Lantz, Carter, Bentzel, Megan, Boyer, David R., Cascio, Duilio, Nguyen, Binh A., Hou, Ke, Cheng, Xinyi, Pardon, Els, Williams, Christopher K., Nana, Alissa L., Vinters, Harry V., Spina, Salvatore, Grinberg, Lea T., Seeley, William W., Steyaert, Jan, Glabe, Charles G., Ogorzalek Loo, Rachel R., Loo, Joseph A., Eisenberg, David S. · 2023 · Proceedings of the National Academy of Sciences
Cited by 47

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Despite much effort, antibody therapies for Alzheimer’s disease (AD) have shown limited efficacy. Challenges to the rational design of effective antibodies include the difficulty of achieving specific affinity to critical targets, poor expression, and antibody aggregation caused by buried charges and unstructured loops. To overcome these challenges, we grafted previously determined sequences of fibril-capping amyloid inhibitors onto a camel heavy chain antibody scaffold. These sequences were designed to cap fibrils of tau, known to form the neurofibrillary tangles of AD, thereby preventing fibril elongation. The nanobodies grafted with capping inhibitors blocked tau aggregation in biosensor cells seeded with postmortem brain extracts from AD and progressive supranuclear palsy (PSP) patients. The tau capping nanobody inhibitors also blocked seeding by recombinant tau oligomers. Another challenge to the design of effective antibodies is their poor blood–brain barrier (BBB) penetration. In this study, we also designed a bispecific nanobody composed of a nanobody that targets a receptor on the BBB and a tau capping nanobody inhibitor, conjoined by a flexible linker. We provide evidence that the bispecific nanobody improved BBB penetration over the tau capping inhibitor alone after intravenous administration in mice. Our results suggest that the design of synthetic antibodies that target sequences that drive protein aggregation may be a promising approach to inhibit the prion-like seeding of tau and other proteins involved in AD and related proteinopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2300258120

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Metadata

Authors
Abskharon, R., Pan, H., Sawaya, M. R., Seidler, P. M., Olivares, E. J., Chen, Y., Murray, K. A., Zhang, J., Lantz, C., Bentzel, M., Boyer, D. R., Cascio, D., Nguyen, B. A., Hou, K., Cheng, X., Pardon, E., Williams, C. K., Nana, A. L., Vinters, H. V., Spina, S., Grinberg, L. T., Seeley, W. W., Steyaert, J., Glabe, C. G., Ogorzalek Loo, R. R., Loo, J. A., & Eisenberg, D. S.
Venue
Proceedings of the National Academy of Sciences
Published
2023-10-06
Volume
120
Issue
41
Pages
e2300258120-e2300258120
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4387409798
Cited by
47
References
23
FWCI
6.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. https://app.cochat.ai/papers/10.1073/pnas.2300258120
The paper
Abskharon, R., Pan, H., Sawaya, M. R., Seidler, P. M., Olivares, E. J., Chen, Y., Murray, K. A., Zhang, J., Lantz, C., Bentzel, M., Boyer, D. R., Cascio, D., Nguyen, B. A., Hou, K., Cheng, X., Pardon, E., Williams, C. K., Nana, A. L., Vinters, H. V., . . . Eisenberg, D. S. (2023). Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2300258120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.